IZO:CC - Izotropic's Izoview Breast CT Device to be Featured on Advancements TV Show in USA
(TheNewswire)
VANCOUVER, BC – TheNewswire - January 13,2023 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a medical device company , adedicated breast CT (computed tomography) imaging platform, for themore accurate detection and diagnosis of breast cancers, announcestoday that IzoView will be featured on an upcoming segment of Advancements with Ted Danson (“ Advancements ”) via Amazon Prime Video and Bloomberg TV. The Companywill update shareholders when filming for the segment commences on , and will disclose the airing date and timein a formal news release when determined.
The news release issued by Advancements follows:
“ An upcomingSegment of Advancements will Explore theFuture of Breast Imaging
Learn how developments in technologyare improving the outcomes of breast cancer.
Jupiter, FL—An upcoming segment of Advancements with Ted Danson willfocus on innovations in CT imaging tools and technologies.
In this episode, viewers will learn about theincreasing rates of breast cancer, which in recent years has surpassedlung cancer as the most common form. Audiences will learn howdevelopments in CT imaging technology are providing more accuratedetection and diagnosis of breast cancers.
Viewers will learn about Izotropic Corporation’sIzoView Breast CT imaging platform, which produces high resolutionbreast images in true 3D with low radiation dose levels.
“IzoView has the potential to revolutionize breastimaging as we know it”, said Dr. John McGraw, Chief ExecutiveOfficer of Izotropic. “We’re preparing for a clinical studyinitiating this year for market authorization in the USA to bring ourbreast CT technology to hospitals and clinics across the country.IzoView will offer a whole new experience for patients, providers,radiologists, and other surgical and oncology specialists. We’revery proud of our technology and the impact we intend to have onbreast cancer diagnostics to improve the outcomes of breast cancer.”
In addition, the show will discover what makes theplatform ideal for imaging patients with dense breast tissue.
“One 10 second scan acquiresapproximately 500 images. The process is quick and removes the needfor painful breast compression or continual technician breasthandling, providing a more comfortable patientexperience,” said Ed Sullivan, senior producerfor the Advancements series. “We look forward to sharing thisinformation with viewers.”
About Izotropic:
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CTimaging over diagnostic mammography procedures. In follow-on clinicalstudies, Izotropic intends to validate platform applications,including breast screening in radiology, treatment planning andmonitoring in surgical oncology, and breast reconstruction and implantmonitoring in plastic and reconstructive surgery.
For more information, visit https://izocorp.com/
About Advancements and DMGProductions:
Advancements is an information-basededucational television series that explores recent developments takingplace across several industries and economies. Shining a light on important issues and topics impactingsociety today, the series features the cutting-edge improvements,state-of-the-art technologies, and innovative solutions responsiblefor shaping, molding, and transforming our world.
Backed by experts invarious fields, DMG Productions is dedicated to education andadvancement, and to consistently producing commercial-free,educational programming for viewers and networks.
For more information, please visit www.AdvancementsTV.com or call866-496-4065.”
ON BEHALF OF THE BOARD
Investor Relations Contact:
Mr. James Berard
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Ms. Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropicintends to validate platform applications, including breast screeningin radiology, treatment planning and monitoring in surgical oncology,and breast reconstruction and implant monitoring in plastic andreconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify suchinformation and statements by using words such as"anticipate," "believe," "envision,""estimate," "expect," "intend,""may," "plan," "predict,""project," "target," "potential," "will," "would,""could," "should," "continue,""contemplate" and other similar expressions and derivationsthereof in connection with any discussion of future events, trends orprospects or future operating or financial performance, although notall forward-looking statements contain these identifying words.
These statements are not guarantees of performance andinvolve risks, including those related to capital requirements anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company's activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the Company nor its shareholders,officers, and consultants shall be liable for any action and theresults of any action taken by any person based on the informationcontained herein, including, without limitation the purchase or saleof Company securities. Nothing in this document should be deemed to bemedical or other advice of any kind. All images are for illustrativepurposes only. IzoView is not yet approved for sale.
Copyright (c) 2023 TheNewswire - All rights reserved.